Hematology-Oncology
Latest news
316 articles · 20 / page
The 2024 EBMT Activity Report: Crossing One Million HCTs and 20,000 CAR-T, a Landmark in Cellular Therapy
EBMT’s 2024 report marks over one million reported stem cell transplants and continued rapid CAR-T growth, highlighting shifts in indications, donor use, and access across Europe.
Next-Generation Sequencing MRD Detection Predicts Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation
A low-cost NGS-based MRD test detected hidden AML cells before transplant and strongly predicted worse survival after allogeneic stem cell transplantation.
Targeting Ibrutinib Resistance Pathways with miR-28 in ABC-DLBCL
miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.
Regulatory-like FOXP3+Helios+CD4+ T Conventional Cells Correlate with T-Cell Activation After Orca-T Immunotherapy
A study of leukemia patients found that Orca-T transplant therapy increases a regulatory-like CD4+FOXP3+Helios+ T-cell subset early after treatment, and this subset correlates with later T-cell activation, offering a potential biomarker for
Elevated Von Willebrand Factor and Factor VIII Show Promise as Biomarkers for Diagnosis and Monitoring of Chronic Graft-Versus-Host Disease
In a prospective cohort, VWF and FVIII were significantly elevated in chronic graft-versus-host disease, tracked with disease activity, and showed moderate diagnostic performance for early cGvHD.
Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models
MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.
Self-Reinforcing IL-1β Signaling Accelerates TCF3::HLF-Positive B-ALL Development and Relapse
Researchers found that IL-1β signaling drives growth, relapse, and bone damage in TCF3::HLF-positive B-ALL, suggesting IL-1β blockade may offer a new treatment strategy.
Safety and Effectiveness of Rivaroxaban Thromboprophylaxis in ACTH-Dependent Cushing Syndrome
Routine oral rivaroxaban prophylaxis in ACTH-dependent Cushing syndrome was associated with no new VTE events after implementation and no bleeding complications, suggesting it is a safe and effective preventive strategy.
Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma
P85-Ab, an anti-EBV BNLF2b antibody test, showed excellent accuracy for suspected nasopharyngeal carcinoma and outperformed older EBV markers in most outpatient settings.
Frontline Allogeneic Transplantation Outperforms Pretransplant IPSS-M Downstaging in Myelodysplastic Neoplasms
In adults with myelodysplastic neoplasms undergoing allogeneic transplantation, pretransplant cytoreduction modestly improved IPSS-M in some patients but did not improve post-transplant survival and was associated with higher non-relapse mo
Choosing a Stem Cell Donor: Why Age Matters More in Some Transplants Than Others
A major 2026 study suggests donor age affects survival differently in haploidentical and matched unrelated stem cell transplants, offering a more practical framework for choosing the best donor.
CBFB::MYH11 MRD After the Second Chemotherapy Cycle: A Guide to Allogeneic Transplantation in Favorable-Risk AML
Post-cycle 2 CBFB::MYH11 MRD best predicted outcomes in favorable-risk AML. Patients with levels ≥1% had higher relapse risk, and those receiving allo-HCT in CR1 had better 3-year disease-free survival than chemotherapy consolidation.
Comprehensive Mutational Profiling and Clinical Outcomes in Adult AML with NUP98 Rearrangement
Adult AML with NUP98 rearrangements is a high-risk subtype marked by frequent FLT3-ITD and WT1 mutations, poor survival, and potential benefit from FLT3 inhibitors and stem cell transplant.
Evolution of Tumor Subclones and T-Cell Dynamics Underlie Variable Ibrutinib Responses in Waldenström Macroglobulinemia
Single-cell profiling of WM during ibrutinib therapy revealed three tumor evolution patterns, a predictive WIP score, and T-cell dysfunction linked to resistance and disease progression.
Poverty Exposure in Standard-Risk Pediatric B-ALL Is Linked to Steroid-Resistance Programs and an Immunologically Suppressed Leukemia Microenvironment
Single-cell RNA sequencing suggests that childhood poverty exposure is associated with steroid-resistance signatures in leukemic blasts and adverse immune remodeling at diagnosis in standard-risk B-ALL.
Early ctDNA MRD After Two Cycles Identifies Distinct Relapse Risk Groups in Advanced Hodgkin Lymphoma
In the GHSG HD21 trial, a validated ctDNA assay showed that MRD positivity after two treatment cycles strongly predicted inferior progression-free survival and improved early risk stratification, especially when combined with interim PET.
Molecular Profiling Refines Relapse Risk After Allogeneic Transplant in First-Remission Acute Myeloid Leukemia
A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.
A New CTCL-Specific Quality-of-Life Tool Shows Strong Early Validity Signals in Cutaneous T-Cell Lymphoma
A single-center validation study suggests the CTCL-PRO-20 may provide a reliable, disease-specific measure of quality of life in patients with cutaneous T-cell lymphoma.
CAR T-Cell Therapy Targeting CD117 Shows Promise Against Advanced Systemic Mastocytosis in Preclinical Studies
Anti-CD117 CAR T-cell therapy demonstrated potent elimination of malignant mast cells in preclinical models of advanced systemic mastocytosis, offering a potential new treatment approach for this aggressive disorder.
Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell Lymphoma
A retrospective study of 584 Australian lymphoma patients shows no significant link between CAR T-cell infusion timing and treatment outcomes, suggesting chronobiology may not influence results in large B-cell lymphoma therapy.
Browse by specialty
Open language-specific specialty feeds and department pages.